These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 9245486)

  • 1. The inhibitory effect of rolipram on TNF-alpha production in mouse blood ex vivo is dependent upon the release of corticosterone and adrenaline.
    Pettipher ER; Eskra JD; Labasi JM
    Cytokine; 1997 Aug; 9(8):582-6. PubMed ID: 9245486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Regulation of tumour necrosis factor production by adrenal hormones in vivo: insights into the antiinflammatory activity of rolipram.
    Pettipher ER; Labasi JM; Salter ED; Stam EJ; Cheng JB; Griffiths RJ
    Br J Pharmacol; 1996 Apr; 117(7):1530-4. PubMed ID: 8730750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The phosphodiesterase type 4 (PDE4) inhibitor CP-80,633 elevates plasma cyclic AMP levels and decreases tumor necrosis factor-alpha (TNFalpha) production in mice: effect of adrenalectomy.
    Cheng JB; Watson JW; Pazoles CJ; Eskra JD; Griffiths RJ; Cohan VL; Turner CR; Showell HJ; Pettipher ER
    J Pharmacol Exp Ther; 1997 Feb; 280(2):621-6. PubMed ID: 9023272
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The influence of endogenous catecholamines on the inhibitory effects of rolipram against early- and late-phase response to antigen in the guinea pig.
    Underwood DC; Matthews JK; Osborn RR; Bochnowicz S; Torphy TJ
    J Pharmacol Exp Ther; 1997 Jan; 280(1):210-9. PubMed ID: 8996198
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interleukin-10 does not mediate the inhibitory effect of PDE-4 inhibitors and other cAMP-elevating drugs on lipopolysaccharide-induced tumors necrosis factor-alpha generation from human peripheral blood monocytes.
    Seldon PM; Barnes PJ; Giembycz MA
    Cell Biochem Biophys; 1998; 29(1-2):179-201. PubMed ID: 9631245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SB 207499 (Ariflo), a second generation phosphodiesterase 4 inhibitor, reduces tumor necrosis factor alpha and interleukin-4 production in vivo.
    Griswold DE; Webb EF; Badger AM; Gorycki PD; Levandoski PA; Barnette MA; Grous M; Christensen S; Torphy TJ
    J Pharmacol Exp Ther; 1998 Nov; 287(2):705-11. PubMed ID: 9808700
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rolipram on cyclic AMP levels in alveolar macrophages and lipopolysaccharide-induced inflammation in mouse lung.
    Gonçalves de Moraes VL; Singer M; Vargaftig BB; Chignard M
    Br J Pharmacol; 1998 Feb; 123(4):631-6. PubMed ID: 9517381
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of cell adhesion molecule expression and function on human lung microvascular endothelial cells by inhibition of phosphodiesterases 3 and 4.
    Blease K; Burke-Gaffney A; Hellewell PG
    Br J Pharmacol; 1998 May; 124(1):229-37. PubMed ID: 9630364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipopolysaccharide induces expression of tumour necrosis factor alpha in rat brain: inhibition by methylprednisolone and by rolipram.
    Buttini M; Mir A; Appel K; Wiederhold KH; Limonta S; Gebicke-Haerter PJ; Boddeke HW
    Br J Pharmacol; 1997 Dec; 122(7):1483-9. PubMed ID: 9421299
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exogenous and endogenous catecholamines inhibit the production of macrophage inflammatory protein (MIP) 1 alpha via a beta adrenoceptor mediated mechanism.
    Haskó G; Shanley TP; Egnaczyk G; Németh ZH; Salzman AL; Vizi ES; Szabó C
    Br J Pharmacol; 1998 Nov; 125(6):1297-303. PubMed ID: 9863660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Regulation of IL-15-stimulated TNF-alpha production by rolipram.
    Kasyapa CS; Stentz CL; Davey MP; Carr DW
    J Immunol; 1999 Sep; 163(5):2836-43. PubMed ID: 10453029
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity.
    Xu H; Strassmann G; Chan CC; Rizzo LV; Silver PB; Wiggert B; Caspi RR
    Invest Ophthalmol Vis Sci; 1999 Apr; 40(5):942-50. PubMed ID: 10102291
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A canine model for determination of the therapeutic index of cytokine inhibitors.
    Sekut L; Han B; Baer P; Verghese MW; Silverstein R; Clifton L; Dennis S; Numerick MJ; Connolly KM
    Lab Anim Sci; 1995 Dec; 45(6):647-51. PubMed ID: 8746524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The phosphodiesterase i.v. inhibitor rolipram in vitro reduces the numbers of MBP-reactive IFN-gamma and TNF-alpha mRNA expressing blood mononuclear cells in patients with multiple sclerosis.
    Navikas V; Matusevicius D; Söderström M; Pirskanen R; Fredrikson S; Link H
    Clin Neuropharmacol; 1998; 21(4):236-44. PubMed ID: 9704165
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Striking effect of hydroxamic acid substitution on the phosphodiesterase type 4 (PDE4) and TNF alpha inhibitory activity of two series of rolipram analogues: implications for a new active site model of PDE4.
    Kleinman EF; Campbell E; Giordano LA; Cohan VL; Jenkinson TH; Cheng JB; Shirley JT; Pettipher ER; Salter ED; Hibbs TA; DiCapua FM; Bordner J
    J Med Chem; 1998 Jan; 41(3):266-70. PubMed ID: 9464356
    [No Abstract]   [Full Text] [Related]  

  • 16. Synthesis of tumour necrosis factor-alpha in tissue culture of rat caecum: lack of suppression by phosphodiesterase inhibitors and prostanoids.
    Greten TF; Moeller J; Feldmeier H; Eigler A; Endres S
    Eur J Gastroenterol Hepatol; 1996 Jul; 8(7):679-84. PubMed ID: 8853258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of PDE 4 inhibitors, rolipram and SB 207499 (ariflo), in a rat model of pulmonary neutrophilia.
    Spond J; Chapman R; Fine J; Jones H; Kreutner W; Kung TT; Minnicozzi M
    Pulm Pharmacol Ther; 2001; 14(2):157-64. PubMed ID: 11273798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats.
    Chi ZL; Hayasaka S; Zhang XY; Hayasaka Y; Cui HS
    Invest Ophthalmol Vis Sci; 2004 Aug; 45(8):2497-502. PubMed ID: 15277469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Specific type IV phosphodiesterase inhibitor rolipram mitigates experimental colitis in mice.
    Hartmann G; Bidlingmaier C; Siegmund B; Albrich S; Schulze J; Tschoep K; Eigler A; Lehr HA; Endres S
    J Pharmacol Exp Ther; 2000 Jan; 292(1):22-30. PubMed ID: 10604928
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adrenal hormone deprivation affects macrophage catecholamine metabolism and β2-adrenoceptor density, but not propranolol stimulation of tumour necrosis factor-α production.
    Stanojevic S; Dimitrijevic M; Kustrimovic N; Mitic K; Vujic V; Leposavic G
    Exp Physiol; 2013 Mar; 98(3):665-78. PubMed ID: 23180813
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.